



# Trikafta in Pakistan

*The DRAP named-patient coordination pathway — indicative 2026*

RARE DISEASE · CYSTIC FIBROSIS CFTR MODULATOR

## The clinical situation

Trikafta (elixacaftor/tezacaftor/ivacaftor) is a triple-combination CFTR modulator for cystic fibrosis patients aged 2 years and older with at least one F508del mutation or another responsive CFTR variant. Manufactured by Vertex. Oral once-daily morning tablets plus an evening ivacaftor dose. Transaminase monitoring and paediatric cataract screening are required. Lifelong therapy; treatment gaps rapidly reverse pulmonary gains.

### The pathway, 5 steps

- 1 Consultation & CFTR genotyping.** Your CF team confirms F508del or other responsive variant and writes the clinical rationale letter.
- 2 Baseline assessment.** Liver function, sweat chloride where useful, pulmonary function, and cataract screening for paediatric patients.
- 3 DRAP personal-use import application.** Rationale, genotype report, patient reference, and dosing plan filed under Pakistan personal-use import.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Initiation & monitoring.** Your CF team initiates; transaminases at baseline, 3, 6, and 12 months; continuity planning for lifelong supply.

### Indicative economics

**Reference US cash-pay range:** USD 320,000–340,000 per year (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**21–35 days** from a complete DRAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your CF team and DRAP review, keyed to CFTR genotype and rationale. **Logistics.** Temperature-controlled shipment with importer-of-record handling and continuity planning. **Concierge case lead.** Named point of contact for the family and CF team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating CF physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Trikafta × Pakistan first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/trikafta-pakistan.html](https://reservemed.com/access-guides/trikafta-pakistan.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team